April 10, 2020

Paul Averback, M.D.
Chief Executive Officer and President
Nymox Pharmaceutical Corporation
Bay & Deveaux Streets
Nassau, The Bahamas

       Re: Nymox Pharmaceutical Corporation
           Registration Statement on Form F-3
           Filed April 3, 2020
           File No. 333-237564

Dear Dr. Averback:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Christine Westbrook at 202-551-5019 with any questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    M. Richard Cutler, Esq.